31 reports

  • Respiratory Drugs Market Characteristics
  • Respiratory Drugs Market Segmentation

Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex®...

  • Respiratory Treatment
  • World
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Respiratory Drugs Companies in China
  • Respiratory Drugs Sales Volume

This study focuses on China’s Respiratory Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is...

  • Respiratory Treatment
  • China
  • Demand
  • AstraZeneca China Inc.
  • Zhongmei Shike Pharmaceutical Co., Ltd
  • Respiratory Drugs Sales Volume
  • RESPIRATORY DRUGS INDUSTRY ASSESSMENTS

China’s demand for Respiratory Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...

  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • GlaxoSmithKline plc
  • Respiratory Drugs Market Overview
  • IV. RESPIRATORY DRUGS PRODUCTION AND DEMAND

This study focuses on China’s Respiratory Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...

  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • Trade
  • Respiratory Drugs Sales Volume and Market Share
  • Respiratory Drugs Import Volume and Market Share

This study focuses on China’s Pediatric Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...

  • Respiratory Treatment
  • China
  • Demand
  • Trade
  • Roche Group
  • RESPIRATORY DRUGS MARKET IN EMEA
  • RESPIRATORY DRUGS MARKET IN APAC

About Respiratory Ailments Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases....

  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Respiratory Drugs Sales Volume and Market Share
  • Respiratory Drugs Import Volume and Market Share

China’s demand for Pediatric Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...

  • Respiratory Treatment
  • China
  • Demand
  • GlaxoSmithKline plc
  • Roche Group
  • Respiratory Drugs
  • Respiratory Drugs

This study focuses on China’s Prescription Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...

  • Pharmaceutical
  • Prescription Drug
  • Respiratory Treatment
  • China
  • Demand
  • Global respiratory drugs market
  • Global respiratory drugs market 2015-2020 ($ billions)

About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized...

  • Respiratory Treatment
  • China
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG

You can easily book an appointment with one online.

  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • BOEHRINGER INGELHEIM

It undertakes the development of drugs for the treatment of respiratory disorders.

  • Respiratory Treatment
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Key vendor analysis

Roflumilast (Daliresp) is one such drug available in the market.

  • Respiratory Treatment
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Strength
  • Vendor landscape

About asthma According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty...

  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • CHIESI'S COPD PORTFOLIO ASSESSMENT, 2017
  • 10.3.3 CHIESI

RESPIRATORY RESEARCH; ##(##): ##.

  • Respiratory Treatment
  • Australia
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET

THE GROWING R& D ACTIVITIES TO DEVELOP DRUGS FOR PREVIOUSLY UNTAPPED MARKETS (ELDERLY POPULATION OF AGES MORE THAN ##) IS ONE OF THE BIGGEST UPCOMING TREND FOR THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) DRUGS MARKET.

  • Respiratory Treatment
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • TEVA'S AR PORTFOLIO ASSESSMENT, 2014
  • 4.3.5 TEVA

Primary Care Respiratory Journal; ##(##): ##-##.

  • Respiratory Treatment
  • GlaxoSmithKline plc
  • GlobalData's company
  • Merck & Co., Inc.
  • Sanofi S.A.
  • TEVA'S AR PORTFOLIO ASSESSMENT, 2014

PRIMARY CARE RESPIRATORY JOURNAL; ##(##): ##-##.

  • Respiratory Treatment
  • Japan
  • Market Size
  • Merck & Co., Inc.
  • Sanofi S.A.
  • 10. Market Segmentation by Therapeutic Application
  • 03.2 Product Offerings

About Generic Drugs A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs...

  • Anti-Infective
  • Respiratory Treatment
  • Japan
  • Meiji Seika Pharma Co., Ltd.
  • Nipro Corporation
  • 23.1 COMPETITIVE SCENARIO

Advair is one of the major drugs in its portfolio, followed by Breo Ellipta and Serevent.

  • Respiratory Treatment
  • United States
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • FIVE MAJOR EU MARKETS PAYER INSIGHTS
  • IL-5 INHIBITORS

ONE PAYER ASSERTED THAT THE DRUG IS IN A NON-PREFERRED TIER BECAUSE IT IS NEW TO THE MARKET AND WILL BE REASSESSED DURING A BROAD RESPIRATORY REVIEW.

  • Asthma
  • Respiratory Treatment
  • Therapy
  • ESI Group
  • GlaxoSmithKline plc

Chapter Eight: Other Drug Classifications Table ##-## U. S.

  • Respiratory Treatment
  • United States
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Company Name Business Description
  • Deal Type

Summary Invion Ltd (Invion) is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease.The company’s pipeline products include INV102 nadolol, a beta blocker for inflammatory lung conditions; INV103...

  • Respiratory Treatment
  • Australia
  • Company
  • M&A
  • Invion Limited

Hisamitsu offers OTC products namely, topical antifungal drugs, eye drops, quasi drugs, medical device, cosmetics, and health supplements as well as prescription products such as dermatologic drugs, CNS drugs, and respiratory system drugs to the

  • Incontinence Product
  • OTC
  • Pharmaceutical
  • Respiratory Treatment
  • Therapy
  • SEASONAL ALLERGIC RHINITIS - PIPELINE BY HISAMITSU PHARMACEUTICAL CO., INC., H1 2016

It offers products such as anti-inflammatory pain relieving patches, antifungal drugs, analgesic drugs, dermatological drugs, cosmetics, quasi drugs, respiratory system drugs and others.

  • Allergy Drug
  • OTC
  • Pharmaceutical
  • Respiratory Disease
  • Respiratory Treatment
  • PERENNIAL ALLERGIC RHINITIS - PIPELINE BY HISAMITSU PHARMACEUTICAL CO., INC., H1 2016

It offers products such as anti-inflammatory pain relieving patches, antifungal drugs, analgesic drugs, dermatological drugs, cosmetics, quasi drugs, respiratory system drugs and others.

  • Allergy Drug
  • OTC
  • Pharmaceutical
  • Respiratory Disease
  • Respiratory Treatment
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • Respiratory Treatment
  • World

The company offers products such as anti-tuberculosis, cephalosporins (anti-infectives) and cardiovascular drugs (angiotensin-converting-enzyme (ACE)-inhibitors and cholesterol reducing agents) in the areas of diabetes, antiinflammatory and respiratory therapy.

  • Pharmaceutical
  • Respiratory Treatment
  • United States
  • Company
  • Dainippon Sumitomo Pharma Co., Ltd.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Asthma
  • Clinical Trial
  • Pharmaceutical
  • Respiratory Treatment
  • World

Verona Pharma plc commenced a new trial with its lead respiratory drug, RPL##, at the Centre for Human Drug Research (CHDR) in the Netherlands.

  • Respiratory Disease
  • Respiratory Treatment
  • Therapy
  • United States
  • Infinity Pharmaceuticals, Inc.
  • Clinical Trial Profile Snapshots

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Clinical Trial
  • Hospital
  • Pharmaceutical
  • Respiratory Treatment
  • World